Kaken reports JPY 30.15 billion revenue: Kaken Pharmaceutical stock gets JPY 4,575 target
Published on 10/14/2026 at 02:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings and valuation context
- On August 7, 2026, Kaken Pharmaceutical reported JPY 30.15 billion in first-quarter revenue.
- First-quarter net income reached JPY 8.44 billion for fiscal 2027.
- Four analysts gave Kaken Pharmaceutical a consensus target of JPY 4,575 on October 10, 2026.
Kaken Pharmaceutical (JP3207000005) reported JPY 30.15 billion in revenue for the first quarter of fiscal 2027, according to JPX Market Explorer on August 7, 2026. The same report cited JPY 8.44 billion in net income, while Yahoo Finance lists earnings of JPY 8.44 billion for the quarter.
First-quarter earnings reset the baseline
JPX Market Explorer said revenue increased 59.80 percent year over year in the first quarter, giving Kaken Pharmaceutical a sharply stronger opening period than the prior-year comparison. The period ended June 30, 2026, and basic earnings per share reached JPY 222.85.
The earnings mix is important because the company generated JPY 10.90 billion in operating income in the quarter. That figure puts the first three months of fiscal 2027 at the center of the valuation debate, rather than leaving the stock story dependent on revenue growth alone.
What the first quarter means
JPX Market Explorer reported full-year fiscal 2027 guidance of JPY 89.90 billion in sales, JPY 7.90 billion in operating profit and JPY 6.50 billion in net income. First-quarter net income of JPY 8.44 billion already exceeded that full-year net-income guide, although the quarterly result does not by itself establish the final annual outcome.
For the market, the comparison creates both support and a demanding benchmark. Kaken must sustain the first-quarter earnings pace through the remaining three quarters for the initial result to translate into a broader forecast revision.
Stock stays below its yearly high
Kaken Pharmaceutical was last at JPY 3,770.00 on the Tokyo Stock Exchange on October 14, 2026 at 9:28 a.m. JST. The quote was 15.19 percent below the 52-week high of JPY 4,445.00 and the market capitalization was JPY 142.8 billion.
According to Minkabu on October 10, 2026, four analysts held a neutral consensus and an average target of JPY 4,575.00. That target lies 21.35 percent above the Tokyo price, keeping the earnings delivery and the pace of future revisions central to the valuation.
Tokyo quote and valuation
The Tokyo quote of JPY 3,770.00, the JPY 3,540.00 52-week low and the JPY 4,445.00 high frame the current market value as of October 14, 2026. Kaken Pharmaceutical is a specialty and generic drug manufacturer whose portfolio also includes medical devices and agricultural chemicals.
Kaken Pharmaceutical key facts
- Company: Kaken Pharmaceutical Co., Ltd.
- ISIN: JP3207000005
- Ticker: 4521
- Primary exchange: Tokyo Stock Exchange Prime Market
- Primary exchange price as of October 14, 2026 at 9:28 a.m. JST: JPY 3,770.00
- Market capitalization: JPY 142.8 billion as of October 14, 2026
- 52-week range: JPY 3,540.00-4,445.00 as of October 14, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report Nikkei 225.
